Tealwood Asset Management Inc. Grows Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Tealwood Asset Management Inc. boosted its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 0.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 37,410 shares of the company’s stock after purchasing an additional 290 shares during the quarter. Tealwood Asset Management Inc.’s holdings in AstraZeneca were worth $2,451,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. FMR LLC raised its stake in AstraZeneca by 1.1% in the third quarter. FMR LLC now owns 23,117,447 shares of the company’s stock valued at $1,801,080,000 after buying an additional 258,477 shares in the last quarter. Franklin Resources Inc. increased its holdings in shares of AstraZeneca by 8.7% in the 3rd quarter. Franklin Resources Inc. now owns 19,122,675 shares of the company’s stock valued at $1,492,649,000 after acquiring an additional 1,522,715 shares during the last quarter. Fisher Asset Management LLC raised its position in shares of AstraZeneca by 5.3% during the 3rd quarter. Fisher Asset Management LLC now owns 10,480,160 shares of the company’s stock worth $816,509,000 after acquiring an additional 524,175 shares in the last quarter. Clearbridge Investments LLC lifted its stake in AstraZeneca by 5.8% during the second quarter. Clearbridge Investments LLC now owns 3,403,748 shares of the company’s stock worth $265,458,000 after purchasing an additional 186,010 shares during the last quarter. Finally, Bank of Montreal Can boosted its holdings in AstraZeneca by 109.6% in the third quarter. Bank of Montreal Can now owns 3,071,333 shares of the company’s stock valued at $238,397,000 after purchasing an additional 1,605,758 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Analysts Set New Price Targets

AZN has been the topic of a number of research analyst reports. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, AstraZeneca presently has an average rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Stock Down 1.9 %

Shares of NASDAQ:AZN opened at $65.73 on Tuesday. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $87.68. The stock has a market cap of $203.80 billion, a P/E ratio of 31.45, a P/E/G ratio of 1.19 and a beta of 0.46. The firm has a fifty day moving average price of $66.00 and a 200 day moving average price of $74.78. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71.

AstraZeneca (NASDAQ:AZN) last released its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The business had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. During the same quarter in the previous year, the company posted $0.87 earnings per share. The company’s revenue for the quarter was up 18.0% compared to the same quarter last year. Sell-side analysts predict that AstraZeneca PLC will post 4.11 EPS for the current year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.